PTO/SB/08B (08-03)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known		
OIPE				Application No.	10/823,377	
	19NFO	RMATION D	ISCLOS	Filing Date:	April 12, 2004	
AND AND STATEMENT BY APPLICANT (Use as many sheets as necessary) 1 of 2					First Named Inventor	Groneberg
					Art Unit	1625
					Examiner Name	Seaman, D. Margaret
SHEEK		11	of	2	Attorney Docket Number	03-086-A
				U.S. PATENT D	OCUMENTS	
Examiner Initials*	Cite No.1	Document Nu	mber	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant
		Number-Kind Cod	e ^{2 (if known)}			Figures Appear
						

			FOREIGN PATENT	DOCUMENTS			
Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	of Pa	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)		Cited Document	Wh		 T ⁸
/MS/	1	WO 2004/054584 – A1	07-01-2004	Merck & Co., Inc.			
/MS/	2	EP 0035868 - A	09-16-1981	Takeda Yakuhin Kogyo K.I	ζ.		
/MS/	3	WO 02/076964 – A	10-03-2002	Sanofi-Synthelabo			×
/MS/	4	WO 97/25315 – A	07-17-1997	Sanofi			Abs X
·							Abs
	-						
Examiner Signature		/D Margaret Seaman/		Date Consid		05/29/2007	<u></u>

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to compete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO				Complete if Known			
				Application No.	10/823,377		
	INFORMATION DIS	SCLOS	URE	Filing Date:	April 12, 2004		
	STATEMENT BY A			First Named Inventor	Groneberg		
				Art Unit	1625		
(Use as many sheets as necessary)			ry)	Examiner Name	Seaman, D. Margaret		
Sheet	2	of	2	Attorney Docket Number	03-086-A		

		NON PATENT LITERATURE DOCUMENTS				
Examiner Initials* Cite No.1 /MS/ 5		Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published				
		JESSELL et al., "Pain and Analgesia" in <u>Principles of Neural Science, 3rd Edition</u> , 1991, E.R. Kandel, J.H. Schwar T.M. Jessell, editors, pp. 385-399.				
$oxed{oxed}$	6	M.J. MILLAN, "The Induction of Pain: An Integrative Review," Prog. Neurobiol., 1999, 57:1-164.	•			
	7	REGOLI et al., "Pharmacology of Bradykinin and Related Kinins," Pharmacological Rev., 1980, 32(1):1-46.	.			
	8	MENKE et al., "Expression Cloning of a Human B ₁ Bradykinin Receptor," J. Biol. Chem., 1994, 269:21583-21586.	٠٠,			
	9	HESS et al., "Cloning and Pharmacological Characterization of a Human Bradykinin (BK-2) Receptor," Biochem. Biophys. Res. Commun., 1992, 184:260-268.				
	10	F. MARCEAU et al., "Kinin B ₁ receptors: a review," Immunopharmacology, 1995, 30:1-26.				
	11	E.J. COREY et al., "Highly Enantioselective Borane Reduction of Ketones Catalyzed by Chiral Oxazaborolidines. Mechanism and Synthetic Implications," J. Am. Chem. Soc., 1987, v. 109, pp. 5551-5553.	4.			
	12	T. OHKUMA et al., "Practical Enantioselective Hydrogenation of Aromatic Ketones," J. Am. Chem Soc., 1995, v. 117, pp. 2675-2676.	nak i			
	13	THOMPSON et al., "Direct Conversion of Activated Alcohols to Azides Using Diphenyl Phosphoroazidate. A				
		Practical Alternative to Mitsunobu Conditions," J. Org. Chem., 1993, 58 (22):5886-5888.	`` ! :			
	14	DG BATT et al., "Disubstituted Indazoles as Potent Antagonists of the Integrin $\alpha_{\nu}\beta_{3}$," Journal of Medicinal Chemistry, 2000, 43:41-58.	. ! ;			
	15	G. WAGNER et al., "Synthesis of 3-(p- and m-amidinophenyl-3-arylsulfonylaminopropionic acid amide hydroiodides," <i>Chemical Abstracts</i> , March 29, 1982, 96(13), abstract no. 104710e.				
/MS	/ 16	G. WAGNER et al., "Synthese von 3-(p- und m-Amidinophenyl)-3- arylsulfonylaminopropionsäureamidhydroiodiden," <i>Pharmazie</i> , 1981, 36(9):607-609.				

Examiner Signature	/D Margaret Seaman/	Date Considered	05/29/2007	•

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). *See Kinds Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *S Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. *Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to compete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.